Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer

Cancer Immunology, Immunotherapy

Volumn 60, Issue 5, 2011, Pages 715-730

  He, Qiushan ^a,c   Li, Jinlong ^b   Yin, Weihua ^b   Song, Zhichun ^a   Zhang, Zhen ^b   Yi, Tienan ^c   Tang, Jia ^a   Wu, Demin ^a   Lu, Yue ^a   Wang, Zhen ^a   Liu, Dan ^a   Zhang, Xiaoren ^a   Hu, Zhiming ^b,d   Gao, Jimin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d NONE   (China)

Author keywords

Cancer immunochemotherapy; Granulocyte macrophage colony stimulating factor; Paclitaxel; Vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR SURFACE MODIFIED TUMOR CELL VACCINE; PACLITAXEL; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG TUMOR LEVEL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; PACLITAXEL; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 79955549394     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0988-4     Document Type: Article

References (47)

1. DM Parkin F Bray J Ferlay, et al. 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 15761078 10.3322/canjclin.55.2.74 (Pubitemid 40372904)
2. JJ Coen AL Zietman H Thakral, et al. 2002 Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases J Clin Oncol 20 3199 3205 12149291 10.1200/JCO.2002.01.086 (Pubitemid 34831515)
3. KA Roehl M Han CG Ramos, et al. 2004 Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients:long-term results J Urol 172 910 914 15310996 10.1097/01.ju.0000134888.22332.bb (Pubitemid 39096421)
4. TA Stamey CM Yemoto JE McNeal, et al. 2000 Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens J Urol 163 1155 1160 10737486 10.1016/S0022-5347(05)67713-0 1:STN:280:DC%2BD3c7pvFOntQ%3D%3D (Pubitemid 30169382)
5. F Calabro CN Sternberg 2007 Current indications for chemotherapy in prostate cancer patients Eur Urol 51 17 26 17007996 10.1016/j.eururo.2006.08.013 1:CAS:528:DC%2BD2sXhtFWrt78%3D (Pubitemid 44821528)
6. IF Tannock R de Wit WR Berry 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512 15470213 10.1056/NEJMoa040720 1:CAS:528:DC%2BD2cXot1Kmu7s%3D (Pubitemid 39315317)
7. DP Petrylak CM Tangen MH Hussain, et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520 15470214 10.1056/NEJMoa041318 1:CAS:528:DC%2BD2cXot1Kmu7c%3D (Pubitemid 39315318)
8. Jeske S, Tagawa ST, Olowokure O et al (2010) Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urol Oncol [Epub ahead of print]
9. A Sella N Yarom A Zisman, et al. 2009 Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer Oncology-Basel 76 442 446 1:CAS:528:DC%2BD1MXmtFCis7g%3D
10. H Pandha J Eaton R Greenhalgh, et al. 2005 Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy Cancer Gene Ther 12 572 578 15803141 10.1038/sj.cgt.7700836 1:CAS:528:DC%2BD2MXktFOisbg%3D (Pubitemid 40686597)
11. MA Suckow WR Wolter M Pollard 2005 Prevention of de novo prostate cancer by immunization with tumor-derived vaccines Cancer Immunol Immunother 54 571 576 15685450 10.1007/s00262-004-0612-y 1:CAS:528:DC%2BD2MXjtlehsbY%3D (Pubitemid 40603196)
12. DB Moody JC Robinson CM Ewing, et al. 1994 Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo Prostate 24 244 251 8170837 10.1002/pros.2990240505 1:CAS:528:DyaK2cXltVKhtLs%3D (Pubitemid 24166952)
13. R Eager J Nemunaitis 2005 GM-CSF gene-transduced tumor vaccines Mol Ther 12 18 27 15963916 10.1016/j.ymthe.2005.02.012 1:CAS:528:DC%2BD2MXlt1Gls78%3D (Pubitemid 40862352)
14. JW Simons B Mikhak JF Chang, et al. 1999 Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 59 5160 5168 10537292 1:CAS:528:DyaK1MXmvFels7k%3D (Pubitemid 29503977)
15. CS Higano JM Corman DC Smith, et al. 2008 Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer Cancer 113 975 984 18646045 10.1002/cncr.23669 1:CAS:528:DC%2BD1cXhtFSlur3F
16. EJ Small N Sacks J Nemunaitis, et al. 2007 Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer Clin Cancer Res 13 3883 3891 17606721 10.1158/1078-0432.CCR-06-2937 1:CAS:528:DC%2BD2sXntFymtrg%3D (Pubitemid 47037595)
17. JW Simons MA Carducci B Mikhak, et al. 2006 Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer Clin Cancer Res 12 3394 3401 16740763 10.1158/1078-0432.CCR-06-0145 1:CAS:528: DC%2BD28XltFyis7g%3D
18. C Moon JC Park YK Chae, et al. 2008 Current status of experimental therapeutics for prostate cancer Cancer Lett 266 116 134 18440696 10.1016/j.canlet.2008.02.065 1:CAS:528:DC%2BD1cXnsFCnsL4%3D
19. J Gao S Huang M Li, et al. 2006 GM-CSF-surface-modified B16.F10 melanoma cell vaccine Vaccine 24 5265 5268 16713660 10.1016/j.vaccine.2006.04.031 1:CAS:528:DC%2BD28Xltlenu7w%3D (Pubitemid 43818206)
20. Z Hu W Tan L Zhang, et al. 2010 A novel immunotherapyfor superficial bladder cancer by intravesical immobilization of GM-CSF J Cell Mol Med 14 1836 1844 19627402 10.1111/j.1582-4934.2009.00818.x 1:CAS:528:DC%2BC3cXhsFyrtLjN
21. RA Prell L Gearin A Simmons, et al. 2006 The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration Cancer Immunol Immunother 55 1285 1293 16408214 10.1007/s00262-005-0116-4 1:CAS:528:DC%2BD28Xmtl2qurs%3D (Pubitemid 43992054)
22. Y Eralp X Wang JP Wang, et al. 2004 Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model Breast Cancer Res 6 R275 R283 15217493 10.1186/bcr787 1:CAS:528:DC%2BD2cXkvVGmu7Y%3D
23. JP Machiels L Duck B Honhon, et al. 2005 Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study Ann Oncol 16 1898 1905 16219623 10.1093/annonc/mdi406 (Pubitemid 41724278)
24. A Chopra TS Kim I O-Sullivan, et al. 2006 Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine Int J Cancer 118 2888 2898 16380982 10.1002/ijc.21724 1:CAS:528:DC%2BD28Xks1Sisbc%3D (Pubitemid 43673373)
25. CT Garnett J Schlom JW Hodge 2008 Combination of docetaxel and recombinant vaccine enhances T cell responses and antitumor activity: effects of docetaxel on immune enhancement Clin Cancer Res 14 3536 3544 18519787 10.1158/1078-0432.CCR-07-4025 1:CAS:528:DC%2BD1cXmslygtrc%3D
26. M Noguchi T Kakuma H Uemura, et al. 2010 A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer Cancer Immunol Immunother 59 1001 1009 20146063 10.1007/s00262-010-0822-4 1:CAS:528:DC%2BC3cXlsVWmtbw%3D
27. PM Arlen JL Gulley C Parker, et al. 2006 A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer Clin Cancer Res 12 1260 1269 16489082 10.1158/1078-0432.CCR-05-2059 1:CAS:528:DC%2BD28XhsFaltb8%3D (Pubitemid 43342517)
28. AL Zhang PJ Russell 2006 Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice Cancer Lett 233 185 191 15927363 10.1016/j.canlet.2005.03.051 1:CAS:528:DC%2BD28XhtlGhsL0%3D (Pubitemid 43214578)
29. MB Lutz N Kukutsch AL Ogilvie, et al. 1999 An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow J Immunol Methods 223 77 92 10037236 10.1016/S0022-1759(98)00204-X 1:CAS:528:DyaK1MXksFOjsw%3D%3D (Pubitemid 29096240)
30. HN El N Rubio J Blanco 2005 Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase Clin Cancer Res 11 1253 1258 (Pubitemid 40175778)
31. E Sato SH Olson J Ahn, et al. 2005 Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci USA 102 18538 18543 16344461 10.1073/pnas.0509182102 1:CAS:528:DC%2BD28Xpt1Om (Pubitemid 43011261)
32. GS Huang L Lopez-Barcons BS Freeze, et al. 2006 Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice Clin Cancer Res 12 298 304 16397055 10.1158/1078-0432.CCR-05-0229 1:CAS:528:DC%2BD28Xht1GrsA%3D%3D (Pubitemid 43166207)
33. JP Machiels RT Reilly LA Emens, et al. 2001 Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 61 3689 3697 11325840 1:CAS:528:DC%2BD3MXjsFCgur8%3D (Pubitemid 32694981)
34. L Conti S Gessani 2008 GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances Immunobiology 213 859 870 18926300 10.1016/j.imbio.2008.07.017 1:CAS:528:DC%2BD1cXhtlCgt7zO
35. B Bodey Jr B Bodey SE Siegel, et al. 2000 Failure of cancer vaccines: the significant limitations of this approach to immunotherapy Anticancer Res 20 2665 2676 10953341 1:CAS:528:DC%2BD3cXlvFGjtbs%3D (Pubitemid 30614482)
36. AP Vicari R Luu NR Zhang, et al. 2009 Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse Cancer Immunol Immunother 58 615 628 18802696 10.1007/s00262-008-0586-2 1:CAS:528:DC%2BD1MXht1Olsbk%3D
37. MD Galsky NJ Vogelzang 2010 Docetaxel-based combination therapy for castration-resistant prostate cancer Ann Oncol 21 2135 2144 20351071 10.1093/annonc/mdq050 1:STN:280:DC%2BC3cbhtl2htg%3D%3D
38. OT Chan LX Yang 2001 The immunological effects of taxanes Cancer Immunol Immunother 49 181 185 10.1007/s002620000122 (Pubitemid 30484824)
39. R Zagozdzon J Golab 2001 Immunomodulation by anticancer chemotherapy: more is not always better Int J Oncol 18 417 424 11172612 1:CAS:528: DC%2BD3MXnvF2ltg%3D%3D
40. B Yu S Kusmartsev F Cheng, et al. 2003 Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer Clin Cancer Res 9 285 294 12538481 1:CAS:528:DC%2BD3sXnt1Orsw%3D%3D (Pubitemid 36109745)
41. H Zhong B Han IL Tourkova, et al. 2007 Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth Clin Cancer Res 13 5455 5462 17875775 10.1158/1078-0432.CCR- 07-0517 1:CAS:528:DC%2BD2sXhtVCitL3M (Pubitemid 47510373)
42. L Zhang K Dermawan M Jin, et al. 2008 Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy Clin Immunol 129 219 229 18771959 10.1016/j.clim.2008.07.013 1:CAS:528:DC%2BD1cXht1Kgt7zE
43. GV Shurin IL Tourkova MR Shurin 2008 Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells J Immunother 31 491 499 18463535 10.1097/CJI.0b013e318176fae4 1:CAS:528:DC%2BD1cXmsFyrs7g%3D
44. + T cell-mediated antitumor immunity induced by vaccination with vaccinia virus Mol Ther 15 1558 1563 17551502 10.1038/sj.mt.6300221 1:CAS:528: DC%2BD2sXhtVejt7jE (Pubitemid 47099313)
45. S Wada K Yoshimura EL Hipkiss, et al. 2009 Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model Cancer Res 69 4309 4318 19435909 10.1158/0008-5472.CAN-08-4102 1:CAS:528: DC%2BD1MXlvFWltLc%3D
46. Y Chu LX Wang G Yang, et al. 2006 Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma J Immunother 29 367 380 16799332 10.1097/01.cji.0000199198.43587.ba 1:CAS:528:DC%2BD28XmtFegs7g%3D (Pubitemid 44288949)
47. ES Antonarakis CG Drake 2010 Current status of immunological therapies for prostate cancer Curr Opin Urol 20 241 246 20179598 10.1097/MOU. 0b013e3283381793